Medical Device | January 10, 2024
Bruker acquires Tornado Spectral Systems to expand biopharma PAT product portfolio
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
The acquisition of the shares of Adita result in growth opportunities in line with strategic objectives of the company
The deal includes upfront payments, milestone payments and ongoing royalties
The company has received five final approvals
AMP-6 & AMP-8 are special purpose entities formed for purpose of setting up captive solar power projects in Karnataka
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
The product is expected to be launched in December 2023
Subscribe To Our Newsletter & Stay Updated
